Temozolomide

Temozolomide__AGT inhibitor SCH900777

Product Name Temozolomide
Description

AGT inhibitor

Purity >99% (TLC); NMR(Conforms)
CAS No. 85622-93-1
Molecular Formula C6H6N6O2
Molecular Weight 194.2
Storage Temperature -20ºC
Shipping Temperature Shipped Ambient
Product Type Inhibitor
Solubility Soluble in DMSO (25 mg/ml, warm) or water (weakly)
Source Synthetic
Appearance Off white powder
SMILES CN1C(=O)N2C=NC(=C2N=N1)C(=O)N
InChI InChI=1S/C6H6N6O2/c1-11-6(14)12-2-8-3(4(7)13)5(12)9-10-11/h2H,1H3,(H2,7,13)
InChIKey BPEGJWRSRHCHSN-UHFFFAOYSA-N
Safety Phrases Classification: Toxic
Safety Phrases:
S22 – Do not breathe dust.
S24/25 – Avoid contact with skin and eyes
S36/37/39 – Wear suitable protective clothing, gloves and eye/face protection
Hazard Phrases:
H302 Harmful if swallowed.
H315 Causes skin irritation.
H319 Causes serious eye irritation.
H335 May cause respiratory irritation.
H350 May cause cancer.
H360 May damage fertility or the unborn child.
Precautionary Phrases:
P201 Obtain special instructions before use.
P261 Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P308 + P313 IF exposed or concerned: Get medical advice or attention.
Cite This Product Temozolomide (StressMarq Biosciences Inc., Victoria BC CANADA, Catalog # SIH-363)
Alternative Names 3-Methyl-4-oxo-3,4-dihydroimidazo5,1-d1,2,3,5tetrazine-8-carboxamide; 8-Carbamoyl-3-methylimidazo5,1-d-1,2,3,5-tetrazin-4(3H)-one
Research Areas Cancer, Apoptosis
PubChem ID 5394
Scientific Background Temozolomide is a membrane permeable DNA alkylating agent which acts as an anti-tumor and anti-angiogenic agent by alkylating the N-7 or O-6 positions of guanine residues which triggers tumor cell death (1-2). It has been used clinically as an anti-cancer agent (3) and has been found to induce autophagy in a variety of cell lines (4).
References 1. Kurzen H., et al. (2003) Anticancer Drugs. 14: 515.
2. Gunther W., et al. (2003) Br. J. Cancer. 88: 463.
3. Danson S.J., et al. (2001) Expert Rev. Anticancer Ther. 10: 13.
4. Natsumeda M., et al. (2011) Neuropathology. 31: 486.